Introduction: Serous cystadenomas are benign tumors and represent about 30% of primary cystic neoplasms of the pancreas. Duodenal wall invasion with erosion and bleeding is an extremely rare cause of gastrointestinal bleeding from such lesions. Case Report: An 84-year-old female with a past medical history of a small benign pancreatic head mass which had been asymptomatic for 2 decades was admitted with recurrent melena. Two years prior, she developed epigastric pain and obstructive jaundice. She was found to have an enlarging pancreatic mass requiring endoscopic retrograde cholangiopancreatography (ERCP) with sphincterotomy and biliary metal stent placement. Her current presentation included recurrent melena for 1 week. She did not have any pain, nausea, vomiting, abdominal fullness, or weight loss. Vital signs were within normal limits. On physical examination, mild epigastric tenderness was present. Laboratory studies revealed hemoglobin of 6.6 g/dL, hematocrit of 21%, normal comprehensive metabolic profi le, and normal serum lipase. Computed tomography (CT) angiography 3-dimensional imaging showed a large 10.9 x 8.2-cm heterogeneously enhancing mass in the head of the pancreas (Figure 1 ) and mild-biliary dilatation. On upper endoscopy, an infi ltrating mass in the fi rst and second segments of the duodenum was seen, but no active bleeding was seen. Endoscopic ultrasound (EUS) revealed a large, multi-septate anechoic lesion with cysts of varying sizes in the head of the pancreas causing superior mesenteric
Introduction: Bevacizumab binds to and inhibits vascular endothelial growth factor (VEG-F). In theory, blocking of VEG-F could enhance the severity of acute pancreatitis. We searched the FDA Adverse Event Reporting System (FAERS) database for cases of pancreatitis potentially related to bevacizumab use. Methods: Using the FAERS database, 3,171,655 individual adverse event reports between January 2003 and June 2012 were downloaded and analyzed using SPSS 20 (IBM Co, Armonk, NY, USA). A search was undertaken for reactions of "pancreatitis" with bevacizumab, regardless of indication. All reports were then limited to "primary suspect" cases for bevacizumab, meaning the reporter believed that bevacizumab was the main cause of drug-induced pancreatitis. Th e identifi ed cases were organized with respect to indication for bevacizumab use, age, gender, and type of pancreatitis. In addition, a PubMed search was conducted using the MESH terms "pancreatitis" and "bevacizumab", separated by the Boolean operator "AND". Results: Total of 116 cases of pancreatitis were identifi ed in FAERS, including 22 cases of acute pancreatitis, 1 case of hemorrhagic pancreatitis, and 2 cases of necrotizing pancreatitis. Th e average age of patients reported was 54.6 years, with females accounting for 55%. Th e most common indication for bevacizumab use in this patient group was colorectal cancer (44 cases). Deaths were reported in 11 cases (9.5%). No previously described cases of bevacizumab-associated pancreatitis were found in the medical literature. Conclusion: A small number of cases describing the association of bevacizumab with pancreatitis have been reported to FAERS. Despite the use of bevacizumab in patients with underlying cancer, mortality from pancreatitis in this setting appears to be uncommon. Introduction: Biliary adenomas are rare entities that are usually detected incidentally in gallbladders removed for unrelated indication.Th ey can also occur in the extrahepatic biliary tree, but true incidence is not known.Currently, there is limited understanding of the malignant potential of biliary adenomas involving the extrahepatic tree, and there are no guidelines for management. Th e aim of our study is to analyze a group of patients with extrahepatic biliary tree adenomas and study their clinical course. Methods: Th e pathology database at Baystate Medical Center was used to identify patients diagnosed with biliary adenomas from the year 2000 to 2013. Patients' medical records were reviewed for demographics and clinical course. Results: Pathology results from 8,774 cholecystectomies (with or without bile duct excision) and 1,785 bile duct biopsies over a 13-year period were reviewed.Twenty-three patients with biliary adenoma were identifi ed, arising in the gallbladder (20/23) or the extrahepatic biliary tree (3/23). All 3 patients with extrahepatic biliary adenoma were female, with a mean age of 74 years. On initial presentation, none of the patients had obstructive jaundice. Case 1 had biliary dilation seen on imaging, and endoscopic ultrasound revealed a adenomatous polyp in the distal bile duct. Th e patient refused surgery and presented with occlusive biliary stricture and jaundice 5 months later. Cytology confi rmed malignant progression. Case 2 had history of primary sclerosing cholangitis and presented with cholangitis, gram negative sepsis. A polypoid lesion was seen on imaging in the common hepatic duct, and direct cholangioscopy showed adenoma with high-grade dysplasia. Th e patient underwent successful total bile duct resection and hepaticojejunostomy with good outcome. Case 3 presented with symptoms suggestive of gallbladder pathology and was found to have polypoid distal bile duct lesion on intraoperative cholangiogram. Endoscopic retrograde cholangioscopy showed adenomatous polyp with high-grade dysplasia. Th e patient underwent distal bile duct resection with choledochojejunostomy, but presented with jaundice 4 years later secondary to adenocarcinoma involving small bowel in the Roux limb of jejunum and transverse colon. Conclusion: Adenomas involving the extrahepatic biliary tree are rare benign tumors of the biliary tract. Th ese patients tend to have aggressive clinical course with high risk of subsequent malignancy. Given the poor prognosis associated with cholangiocarcinoma, we suggest aggressive management with total bile duct resection along with hepaticojejunostomy if biliary adenoma is diagnosed outside the gallbladder. Close surveillance for other gastrointestinal malignancies might be warranted. Further analysis of larger databases is recommended.
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Imaging Characteristics, Role of EUS-FNA and Prognosis in Patients With Pancreatic Lymphoma
Hemanth Gavini, MD, MPH, Muhammad Ahmad, MD, Charanjeet Singh, MD, William Ross, MD, Manoop Bhutani, MD, Brian Weston, MD, Jeff rey Lee, MD, MPH, FACG, MD Anderson Cancer Center, Houston, TX. Introduction: Lymphoma involving the pancreas has a prevalence of 2% of all pancreatic malignancy. Th e prognosis and management of pancreatic lymphoma diff er from those of primary pancreatic cancer. Th e purpose of the study was to identify the clinical, imaging, and cytopathology characteristics, 
